CLINICOPATHOLOGICAL SIGNIFICANCE OF PROGRAMED DEATH -LIGAND -1(PD-L1) AND PROLIFERATION CELL NUCLEAR ANTIGE(PCNA)EXPRESSION IN PROSTATIC CARCINOMA; AN IMMUNOHISTOCHEMICAL STUDY"

Expression of programmed death ligand 1 (PD-L1) in urothelial bladder carcinoma (immunohistochemical and histopathological study)

Immunohistochemical expression of programmed death-ligand 1 (PD-L1) in invasive duct carcinoma of the breast of no special type and correlation with patients' clinicopathological

Assessment of PD-L1 and p53 expression in urinary bladder carcinoma: Association with different clinicopathologic characteristics

Association of CTLA4 and PD-L1 immunohistchemical expression with various clinicopathological parameters and survival in non–small-cell lung cancer

Immunohistochemical Study of PDL-1 Expression in Urinary Bladder Carcinoma

The Expression of Immune Checkpoint Inhibitors PDL-1 and CTLA-4 in Pancreatic Versus Non-Pancreatic Periampullary Adenocarcinoma: An Immunohistochemical Study

Immunohistochemical Expression of PDL1 in Invasive Ductal Carcinoma of the Breast

Prognostic Value of Programed Cell Death-1 Ligand Expression in Colorectal Cancer and Its Correlation with Cytotoxic Tumor-Infiltrating Lymphocytes

Evaluation of Serum Programmed Cell Death–1 (PD-1) in Psoriasis Vulgaris: A Case-control Study